LFB and Kedrion sign an industrial cooperation agreement to supply immunoglobulins in France
LFB and Kedrion sign an industrial cooperation agreement to supply immunoglobulins to meet patient demand in France
Les Ulis (France), Castelvecchio Pascoli, Lucca (Italy), (January 31st, 2022) – Two leading European pharmaceutical companies, LFB and Kedrion, are joining forces in an industrial cooperation agreement to increase the availability of immunoglobulin, a plasma-derived medicine, for patients in France.
In the framework of this industrial partnership, Kedrion will manufacture immunoglobulins in Hungary from LFB plasma collected in France by the “Etablissement Français du Sang” (EFS). These immunoglobulins manufactured by Kedrion will be imported by LFB in France and will complement LFB’s own immunoglobulins, which will be made available to hospitals in France, in agreement with and under the control of French health authorities.
“I am delighted with this partnership with Kedrion, which will enable us to meet the growing needs of the French market for immunoglobulins, drugs that are in great demand in France and around the world“, emphasized Denis Delval, LFB’s Chairman and CEO. “Our agreement with Kedrion will provide us with an additional supply of immunoglobulins for patients in France“.
Paolo Marcucci, President of Kedrion, said, “I welcome the cooperation agreement with LFB as it provides a solution for patients in France“. Mr. Marcucci added, “Kedrion shares LFB’s values and its raison d’être, which is to provide products and therapies to patients with serious and often rare diseases“.
About the immunoglobulins made available in France by LFB
LFB fractionates two immunoglobulins, TEGELINE® and CLAIRYG®, from the plasma collected by the “Etablissement Français du Sang” (EFS) in its plants in France and makes them available to patients in France. Moreover, with this industrial agreement with Kedrion, LFB will also make available to patients in France another immunoglobulin, HUMAGLOBIN®, which will be manufactured by Kedrion in its plant in Hungary from plasma collected by the EFS.
About Kedrion Biopharma
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates plasma to produce and distribute worldwide plasma-derived products for the prevention and treatment of rare and debilitating diseases and conditions such as hemophilia, primary immunodeficiencies and RH sensitization.
Headquartered in Tuscany and with more than 2,800 employees worldwide, Kedrion has a commercial presence in 100 countries and is the 5th player in the world, and the 1st in Italy.
Kedrion has manufacturing facilities in Italy, Hungary and North America, and its subsidiary KEDPLASMA operates plasma collection centers in the United States.
Kedrion is a long-standing partner of the Italian National Health System, supporting it in its quest for self-sufficiency in the supply of plasma-derived products.
The company serves as a bridge between donors and those in need of treatment, and works globally to expand patient access to available plasma-derived therapies.
LFB is a biopharmaceutical group that develops, manufactures and markets plasma-derived medicinal products and recombinant proteins for the treatment of patients leaving with serious and often rare diseases. Created in 1994 in France, LFB is today one of the leading European players offering plasma-derived medicinal products to healthcare professionals, with the mission of providing new treatment options for patients in three major therapeutic areas: immunology, hemostasis and intensive care.
LFB currently markets 15 medicines in about 30 countries. For more information, please visit www.groupe-lfb.com